Optic Neuritis – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Optic Neuritis – Pipeline Review, H1 2018’, provides an overview of the Optic Neuritis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Optic Neuritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Optic Neuritis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Optic Neuritis

– The report reviews pipeline therapeutics for Optic Neuritis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Optic Neuritis therapeutics and enlists all their major and minor projects

– The report assesses Optic Neuritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Optic Neuritis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Optic Neuritis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Optic Neuritis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Biogen Inc

Bionure Farma SL

Commence Bio Inc

Lipocure Ltd

Meta-IQ ApS

Mitochon Pharmaceuticals Inc

Teijin Pharma Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Optic Neuritis Overview

Optic Neuritis Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Optic Neuritis Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Optic Neuritis Companies Involved in Therapeutics Development

Biogen Inc

Bionure Farma SL

Commence Bio Inc

Lipocure Ltd

Meta-IQ ApS

Mitochon Pharmaceuticals Inc

Teijin Pharma Ltd

Optic Neuritis Drug Profiles

BN-201 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CMB-200 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ENX-201 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

etomoxir Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gypenoside Drug Profile

Product Description

Mechanism Of Action

R&D Progress

immune globulin (human) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

methylprednisolone sodium succinate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MP-101 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MP-201 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

opicinumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Optic Neuritis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-266 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Optic Neuritis Dormant Projects

Optic Neuritis Discontinued Products

Optic Neuritis Product Development Milestones

Featured News & Press Releases

Jan 31, 2017: Noveome Biotherapeutics Publishes Data Demonstrating Anti-inflammatory Activity of ST266 in a Preclinical Model of Optic Neuritis

Oct 01, 2015: Biogen Presents Phase 2 Data On Anti-LINGO-1 at ECTRIMS Congress

Apr 14, 2015: Biogen Presents New Anti-LINGO-1 Phase 2 Acute Optic Neuritis Data Demonstrating Neurological Repair

Jan 08, 2015: Biogen Idec Reports Positive Top-Line Results From Phase 2 Anti-LINGO-1 Trial In People With Acute Optic Neuritis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Optic Neuritis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Optic Neuritis Pipeline by Biogen Inc, H1 2018

Optic Neuritis Pipeline by Bionure Farma SL, H1 2018

Optic Neuritis Pipeline by Commence Bio Inc, H1 2018

Optic Neuritis Pipeline by Lipocure Ltd, H1 2018

Optic Neuritis Pipeline by Meta-IQ ApS, H1 2018

Optic Neuritis Pipeline by Mitochon Pharmaceuticals Inc, H1 2018

Optic Neuritis Pipeline by Teijin Pharma Ltd, H1 2018

Optic Neuritis Dormant Projects, H1 2018

Optic Neuritis Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Optic Neuritis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports